The Breast Cancer Index appears to perform better than the 21-gene recurrence score in predicting 10-year disease-free survival in postmenopausal women with hormone receptor–positive lymph node–negative early-stage breast cancer. This may have implications for clinical use of first-generation versus second-generation multiparametric genomic assays. Clin Cancer Res; 22(20); 4963–5. ©2016 AACR.
See related article by Sestak et al., p. 5043
- Received July 12, 2016.
- Accepted July 19, 2016.
- ©2016 American Association for Cancer Research.